Learning From Cervical Cancer Survivors: An Examination of Barriers and Facilitators to Cervical Cancer Screening Among Women in the United States.


Journal

Journal of primary care & community health
ISSN: 2150-1327
Titre abrégé: J Prim Care Community Health
Pays: United States
ID NLM: 101518419

Informations de publication

Date de publication:
Historique:
entrez: 6 9 2021
pubmed: 7 9 2021
medline: 21 10 2021
Statut: ppublish

Résumé

Screening and timely follow-up have lowered cervical cancer incidence in the US; however, screening coverage, incidence, and death rates have remained fairly stable in recent years. Studies suggest that half of women diagnosed with cervical cancer don't receive appropriate screening prior to diagnosis; cervical cancer survivors can provide crucial insight into barriers and facilitators to screening. Participants were cervical cancer survivors ≥21 years, identified through population-based central cancer registries (CR) in 3 US states or a social network (SN), Cervivor. CR participants completed a mailed survey on screening history, barriers, and facilitators to screening and sociodemographic data. SN participants completed the same survey online. CR participants (N = 480) were older, with a lower proportion of non-Hispanic white, married, and insured women compared to SN participants (N = 148). Fifty percent of CR and 79% of SN participants were screened 5 years prior to their diagnoses. Of those screened, 28% in both groups reported not following-up on abnormal results. For both groups, the most frequently identified screening barrier was that participants never imagined they would develop cervical cancer (percent agree CR = 76%; SN = 86%), and the facilitator was wanting to take care of their bodies (CR = 95%; SN = 94%). Addressing key barriers to obtaining screening and timely follow-up related to lack of knowledge of cervical cancer risk and screening tests and addressing insurance coverage in the design or modification of interventions may increase cervical cancer screening and lower cervical cancer incidence in the US.

Sections du résumé

BACKGROUND
Screening and timely follow-up have lowered cervical cancer incidence in the US; however, screening coverage, incidence, and death rates have remained fairly stable in recent years. Studies suggest that half of women diagnosed with cervical cancer don't receive appropriate screening prior to diagnosis; cervical cancer survivors can provide crucial insight into barriers and facilitators to screening.
METHODS
Participants were cervical cancer survivors ≥21 years, identified through population-based central cancer registries (CR) in 3 US states or a social network (SN), Cervivor. CR participants completed a mailed survey on screening history, barriers, and facilitators to screening and sociodemographic data. SN participants completed the same survey online.
RESULTS
CR participants (N = 480) were older, with a lower proportion of non-Hispanic white, married, and insured women compared to SN participants (N = 148). Fifty percent of CR and 79% of SN participants were screened 5 years prior to their diagnoses. Of those screened, 28% in both groups reported not following-up on abnormal results. For both groups, the most frequently identified screening barrier was that participants never imagined they would develop cervical cancer (percent agree CR = 76%; SN = 86%), and the facilitator was wanting to take care of their bodies (CR = 95%; SN = 94%).
CONCLUSION
Addressing key barriers to obtaining screening and timely follow-up related to lack of knowledge of cervical cancer risk and screening tests and addressing insurance coverage in the design or modification of interventions may increase cervical cancer screening and lower cervical cancer incidence in the US.

Identifiants

pubmed: 34486436
doi: 10.1177/21501327211041862
pmc: PMC8424614
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

21501327211041862

Subventions

Organisme : NCI NIH HHS
ID : HHSN261201300016C
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U58 DP003915
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201300021C
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U58 DP003921
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201300016I
Pays : United States

Références

Prev Chronic Dis. 2013 Oct 24;10:E173
pubmed: 24157076
Cancer Med. 2021 Jun;10(12):4127-4137
pubmed: 34018674
MMWR Morb Mortal Wkly Rep. 2017 Sep 22;66(37):981-985
pubmed: 28934183
J Am Geriatr Soc. 2008 Feb;56(2):307-14
pubmed: 18070002
Prev Chronic Dis. 2014 Feb 27;11:E29
pubmed: 24576396
Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):529-34
pubmed: 12050093
MMWR Morb Mortal Wkly Rep. 2017 Mar 03;66(8):201-206
pubmed: 28253225
Cancer. 2014 Aug 15;120 Suppl 16:2591-6
pubmed: 25099902
J Womens Health (Larchmt). 2011 Nov;20(11):1579-85
pubmed: 21933006
J Community Health. 2012 Feb;37(1):217-23
pubmed: 21773819
J Natl Cancer Inst. 2005 May 4;97(9):675-83
pubmed: 15870438
J Womens Health (Larchmt). 2014 Jun;23(6):488-92
pubmed: 24707839
J Low Genit Tract Dis. 2008 Jul;12(3):232-41
pubmed: 18596467
Cancer Causes Control. 2015 May;26(5):687
pubmed: 25929885
Cancer. 2000 May 15;88(10):2283-9
pubmed: 10820350
J Immigr Minor Health. 2019 Jun;21(3):606-658
pubmed: 30117005
J Womens Health (Larchmt). 2019 Jul;28(7):890-896
pubmed: 31264934
J Natl Med Assoc. 2005 Feb;97(2):162-70
pubmed: 15712779
J Womens Health (Larchmt). 2011 Apr;20(4):517-24
pubmed: 21413897
Gynecol Oncol. 2013 Apr;129(1):222-8
pubmed: 23280088
J Womens Health (Larchmt). 2013 Sep;22(9):718-23
pubmed: 23930983
J Community Health. 2017 Aug;42(4):770-778
pubmed: 28155005
Curr Oncol. 2014 Dec;21(6):294-304
pubmed: 25489256
J Womens Health (Larchmt). 2014 Mar;23(3):197-203
pubmed: 24380501

Auteurs

Virginia Senkomago (V)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

April Greek (A)

Battelle, Seattle, WA, USA.

J Elizabeth Jackson (JE)

Battelle, Seattle, WA, USA.

Cheryll C Thomas (CC)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Lisa C Richardson (LC)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Vicki B Benard (VB)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH